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headaches, as well as 400 mg of danazol twice daily for 8 weeks
before admission for endometriosis. She denied taking ergota-
mine for her migraine headaches. Family history was negative for
diabetes mellitus, hypertension, autoimmune diseases, coronary
artery disease, and thrombophilia. Physical examination on
admission revealed a well-developed, well-nourished woman in
some distress. The lungs were clear to auscultation bilaterally.
Heart examination revealed a regular heart rate of 85 beats per
minute, without murmur, gallop, or rub. Blood pressure was
140/90 mm Hg. The abdomen was soft and nontender without
bruits or masses. The more symptomatic right foot was cold with
a mottled, ruborous appearance. The left foot was pale with cool
toes. Vascular examination revealed palpable and symmetric
carotid, radial, femoral, and popliteal pulses. No pedal pulses were
palpable on the right, but her left posterior tibial and dorsalis
pedis pulses were weakly palpable. No bruits were appreciated
over the carotid, abdominal, or femoral regions. The neurologic
examination revealed no sensory or motor deficits.
Noninvasive vascular studies of the right lower extremity
revealed ankle-brachial indices (ABIs) of 0.58 and 0.38 with
monophasic Doppler scan waveforms at the dorsal pedis and pos-
terior tibial arteries, respectively. ABIs on the left were 1.02 and
1.05 with triphasic waveforms. Arteriography after admission
revealed normal proximal vessels in both lower extremities with
occlusion of all three major outflow vessels below the popliteal
artery on the right (Fig 1). On the left, her posterior tibial artery
was normal while the anterior tibial and peroneal arteries were
occluded. An extensive work-up during the patient’s admission
included thoracic and abdominal aortography with abdominal
aortic biplanar views, which were negative for atherosclerotic
plaque. Ultrasound scan was negative for aneurysm, and echocar-
diogram was negative for valvular vegetations or mural thrombus.
Blood tests revealed normal prothrombin time and partial throm-
boplastin time. Known causes of coagulopathy were ruled out
without evidence of deficiencies in antithrombin III (>120%; nor-
mal, 80%-120%), protein C (210%; normal, 70%-140%), and pro-
tein S (32 mcg/mL; normal, 13-32 mcg/mL). Screenings for
lupus anticoagulant, factor-V mutation, and prothrombin muta-
tion were all negative. No evidence of increase in lipoprotein(a),
anticardiolipin antibodies, erythrocyte sedimentation rate, or 
fibrinogen was found. Complete blood count on admission
revealed a slightly elevated hemoglobin level at 15.9 and an ele-
vated platelet count at 636,000. Lipid profile was normal with
low-density lipoprotein of 129 and high-density lipoprotein of 37.
Serum homocysteine was 8 µmol (5-15µmol). Endocrinology,
hematology and rheumatology consultations obtained during the
Danazol (Danocrine) is a synthetic androgenic steroid
derived from ethinyl testosterone. It is used in a wide vari-
ety of disorders for its interference in the hypothalamic-
pituitary-gonadal axis as well as its effects on platelet,
anticoagulant, and procoagulant protein levels. Danazol’s
most frequent side effects are androgenic and hypoestro-
genic, and in terms of the coagulation cascade these are
typically thought of as anticoagulant rather than procoag-
ulant events.1 Nevertheless, at least two cases of throm-
botic and thrombophlebitic events have been reported
with this agent.2,3 In addition, cerebral, coronary, and
peripheral arterial thrombosis in young male athletes abus-
ing anabolic-androgenic steroids has been reported and
may be related to alterations in thrombotic balance.4-6
Although there is no convincing evidence that androgens
are thrombogenic in humans, experimental data reveal
that androgens increase platelet levels and aggregation and
alter multiple coagulation proteins.6,7 In this article, we
report two cases of limb-threatening peripheral arterial
occlusion associated with danazol therapy.
CASE REPORT
Case 1. A healthy, 40-year-old, nonsmoking, nondiabetic
woman with no identified risk factors for atherosclerotic disease
was admitted to the Dartmouth-Hitchcock Medical Center with
a 2-week history of increasingly severe bilateral leg cramps and
cold, numb, painful, pale feet. Her symptoms were worse on the
right side. Medical history was significant only for endometriosis
and migraine headaches. The patient did not have a history of
coronary artery disease, cardiac arrhythmia, cancer, deep venous
thrombosis, pulmonary embolus, or any previous arterial throm-
botic events. Medications on admission included 25 mg of
amytriptyline at night, terfenadine, and Fiorinal (aspirin, butal-
bital, and caffeine) and Tylenol No. 3 as needed for migraine
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Danazol is a synthetic androgenic steroid used clinically for the treatment of a wide variety of disorders. Although there
is no extensive evidence that androgens are thrombogenic in humans, there are case reports of cerebral, coronary, and
peripheral arterial thrombosis in young male athletes abusing anabolic-androgenic steroids. There are also two reported
cases of arterial and venous thrombotic events attributed to danazol therapy. We report two additional cases of limb-
threatening arterial thrombosis in patients undergoing danazol therapy, and suggest the possibility that danazol may
be an independent risk factor for arterial thrombosis. (J Vasc Surg 2001;34:1123-6.)
patient’s admission were unable to identify any other potential eti-
ologies for the acute nature of her arterial disease.
Anticoagulant and thrombolytic therapy with systemic intra-
venous heparin and urokinase were initiated after admission;
danazol was held. The patient experienced symptomatic improve-
ment while on urokinase, but her lower-extremity ischemic symp-
toms did not resolve entirely. A subsequent arteriogram revealed
substantial improvement in the appearance of the posterior tibial
artery, but the anterior tibial and peroneal arteries remained
occluded in the midcalf (Fig 2). During the remainder of her
admission, the patient’s ischemic symptoms improved further,
and she was discharged on Coumadin therapy. After discharge,
her symptoms gradually resolved, and right-sided noninvasive vas-
cular laboratory studies normalized. The most recent study
revealed triphasic Doppler scan ankle waveforms at all positions
with normal ABIs throughout. The patient’s Coumadin therapy
was discontinued 1 year later, and she has remained off danazol
therapy without subsequent thrombotic events. Her platelet
count has decreased since discharge and remains in the normal
range. Follow-up arteriogram 14 months later revealed recanal-
ization of the peroneal and posterior tibial arteries (Fig 3).
Case 2. A 71-year-old, nonsmoking, nondiabetic man was
referred to Dartmouth Hitchcock Medical Center with a 3-week
history of ischemic pain in his right lower extremity. The patient’s
pain was worse with exertion but remained when he was at rest.
His medical history was significant for idiopathic thrombocy-
topenic purpura (ITP), and he had been admitted to the hospital
2 months before this presentation for a platelet count of 2,000.
His platelet count responded quickly to intravenous immunoglob-
ulin and an increase in his danazol dose. He had been taking dana-
zol at lower doses for 9 months. His platelet count remained at
normal levels thereafter. The patient’s medical history was also
positive for coronary artery disease with an old myocardial infarc-
tion but no recent symptoms. He also suffered from chronic
obstructive pulmonary disease and colonic polyps treated by colon
resection. The patient had no history of claudication, cardiac
arrhythmia, deep venous thrombosis, or pulmonary embolus. The
patient’s medications at admission included 400 mg of danazol
daily and 45 mg of prednisone daily. Physical examination at
admission revealed an otherwise well-developed, well-nourished
man in moderate distress. Heart examination revealed a regular
heart rate of 75 beats per minute without murmur, gallop, or rub.
The lungs were clear bilaterally, and the abdomen was soft and
nontender without bruits or masses. Vascular examination revealed
palpable and symmetric carotid, radial, and femoral pulses. Right
lower extremity was pale and cool with no palpable pulses below
the femoral artery. He had normal pulses throughout the left
lower extremity. Neurologic examination revealed no motor or
sensory deficits. No Doppler scan signals were obtained on the
right side at the level of the ankle. Laboratory work revealed white
blood cell count of 14.5, a hemoglobin level of 16.2, and a platelet
count of 204,000. Total cholesterol was 183, and serum homo-
cysteine was 9 µmol (5-15 µmol). Known thrombophilic screens
all returned negative including lupus anticoagulant, anticardiolipin
antibody, prothrombin mutation, and methylentetrahydrofolate
reductase mutation.
Arteriogram on admission demonstrated a normal aortic, iliac,
and femoral system above Hunter’s canal without significant ather-
osclerotic disease. His right superficial femoral artery occluded
abruptly just above the knee with reconstitution of a poorly collat-
eralized popliteal artery. The arteriographic appearance suggested
an embolic or thrombotic event, but a thorough diagnostic work-
up failed to reveal an embolic source. Diagnostic testing also did not
reveal evidence of deep venous thrombosis or pulmonary embolus.
Anticoagulant and thrombolytic therapy with intravenous
heparin and urokinase by catheter were initiated the day of admis-
sion with rapid resolution of the patient’s ischemic symptoms.
Noninvasive vascular studies obtained after lytic therapy revealed
ABIs between 1.00 and 1.19 with biphasic dorsal pedis and pos-
terior tibial Doppler waveforms bilaterally. Arteriogram after
thrombolytic therapy revealed complete dissolution of the throm-
bus with excellent blood flow through the superficial femoral and
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Fig 1. Patient 1. A, Arteriogram at admission demonstrating normal proximal arteries. B, Admission arte-
riogram revealed distal occlusion of all three tibial arteries.
A B
popliteal arteries. There was no residual stenosis or evidence of
plaque rupture anywhere in the superficial femoral or popliteal
arteries. The patient was started on Coumadin and discharged 7
days after admission with no further symptoms of vascular insuf-
ficiency. Subsequent noninvasive vascular studies revealed tripha-
sic Doppler scan waveforms at both ankles with ABIs from 0.96
to 1.00. This patient’s Coumadin was discontinued after 6
months. He has remained off danazol therapy and has not suf-
fered any subsequent thrombotic events.
DISCUSSION
Danazol is used primarily for therapy of endometriosis,
and in this setting it has been shown to increase platelet
count.8 However, its clinical profile is expanding, and it is
now also used routinely or experimentally for the manage-
ment of hereditary angioedema, ITP, fibrocystic breast dis-
ease, precocious puberty, gynecomastia, female and male
contraception, systemic lupus erythematous, and for α–1-
antitrypsin deficiency. Danazol is an unusual medication in
that it is used in a variety of disorders to achieve both pro-
thrombotic and antithrombotic effects. Because of its more
well-known antithrombotic effects, danazol has been used
in the management of patients with protein-C deficiency,
protein-S deficiency, and antithrombin-III deficiency.9-11
Danazol’s antithrombotic properties may hinge on its abil-
ity to enhance fibrinolysis and/or inhibit thrombin forma-
tion via elevations in antithrombin III, protein C, protein
S, or plasminogen.9,10,12,13 In contrast, danazol has also
been shown in some studies to effectively treat hemor-
rhagic disorders such as hemophilia A, apparently based on
significant increases in factors VIII and decreased bleeding
episodes in some patients.14,15 Finally, danazol is also used
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in the management of ITP because it has been shown to
increase platelet count in patients with this disorder.16
Although danazol is used clinically to alter the clotting
cascade, there are few reported cases of untoward throm-
botic events with this agent, and to our knowledge the
two cases we present are the first to link danazol to periph-
eral arterial thrombosis. Our first patient had been treated
for endometriosis with danazol for 8 weeks before the
onset of her vascular occlusive symptoms. On admission
she was noted to have an elevated platelet count, which is
a well-known risk factor for thrombotic events. In this
patient, danazol may have been responsible for her ele-
vated platelet count and the subsequent arterial thrombo-
sis, but the pattern of arterial disease appeared much more
complex than a straightforward large-vessel thrombosis.
Unlike those of the second patient, her symptoms did not
resolve completely after thrombolytic therapy, and her
arteriograms demonstrated persistent arterial disease.
The second patient used danazol for management of
his low platelet count associated with ITP, and his
platelet level was within normal limits on admission. This
patient had known coronary artery disease and had suf-
fered a myocardial infarction in the past, but he had no
previous symptoms of peripheral atherosclerotic disease.
His arteriogram on admission did not demonstrate sig-
nificant vascular disease other than the isolated occlusion
of his distal right superficial femoral artery. This vessel
was widely patent after thrombolysis with no evidence of
stenosis or plaque rupture. After an extensive work-up,
which did not reveal an embolic source or known hyper-
coagulable state, we postulated that danazol played a role
in this patient’s arterial thrombosis.
Fig 2. Patient 1. Arteriogram after thrombolytic therapy demon-
strates recanalization of right posterior tibial artery but persistent
occlusion of peroneal and anterior tibial arteries.
Fig 3. Patient 1. Arteriogram 14 months after discharge demon-
strates no substantial further improvement with patency of right
posterior tibial artery but lasting occlusion of the peroneal and
anterior tibial arteries.
Anabolic-androgenic steroids have been implicated in
arterial thrombosis in young athletes without known
thrombotic risk factors.4-6 Danazol itself was implicated in
two separate cases of arterial and venous thrombosis of
cerebral vessels.2,3 The mechanisms by which this class of
androgen contributes to arterial thrombosis or premature
cardiovascular disease are unclear. There is evidence that
they can enhance platelet aggregation by increasing platelet
production of thromboxane A2 and/or decreasing platelet
production of prostaglandin I2, which may contribute to
thrombotic events.6 In addition, danazol has been shown
to increase factors VII and IX in patients with hemophilia
A and B, thereby decreasing bleeding episodes.7 If danazol
produces similar increases in patients without hemophilia,
super-physiologic levels of factor Xa might enhance the
production of thrombin and enhance clot formation. More
studies of danazol and other androgenic-anabolic steroids
are needed to more fully elucidate their effects on hemo-
static mechanisms.
In conclusion, danazol has a complex array of effects on
hemostasis, the sum of which is not well understood. We
have presented two cases of limb-threatening arterial occlu-
sive ischemia in patients on danazol therapy. Although the
pattern of arterial occlusion and the response to throm-
bolytic therapy differed distinctly for these two persons, no
other etiology was identified despite a thorough evaluation,
and they remained free of subsequent thrombotic events
once the danazol was discontinued. These cases illustrate
that danazol may be an independent risk factor for arterial
thrombosis, and physicians who evaluate acute arterial
thrombosis should be aware of this potential complication.
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